Abstract:Guidelines and recommendations developed and endorsed by the International Osteoporosis Foundation (IOF) are intended to provide guidance for particular pattern of practice for physicians who usually prescribe glucocorticoid (GC) therapy, and not to dictate the care of a particular patient. Adherence to the recommendations within this guideline is voluntary and the ultimate determination regarding their application should be made by the physician in light of each patient's circumstances. Guidelines and recommendations are intended to promote a desirable outcome but cannot guarantee any specific outcome. This guideline and its recommendations are not intended to dictate payment, reimbursement or insurance decisions. Guidelines and recommendations are subjected to periodic revisions as a consequence of the evolution of medicine, technology and clinical practice. A panel of Latin American (LATAM) experts specialized in osteoporosis with recognized clinical experience in managing patients with glucocorticoid-induced osteoporosis (GIO) met to produce evidence-based LATAM recommendations for the diagnosis and management of GIO. These guidelines are particularly intended to general practitioners and primary care physicians who prescribe GC treatments in LATAM to guide their daily clinical practice in terms of evaluation, prevention and treatment of GIO. These recommendations were based on systematic literature review using MEDLINE, EMBASE, SCOPUS and COCHRANE Library database during the period from 2012 to 2021. Randomized clinical trials (RCT), systematic reviews of RCT, controlled observational studies, guidelines and consensus were considered. Based on the review and expert opinion the panel members voted recommendations during two successive rounds of voting by panel members. Agreements for each statement were considered if a concordance of at least 70% was achieved following Delphi methodology. Grading of recommendations was made according to the Oxford Centre for the Evidence-based Medicine (EBM) criteria. Among five GIO guidelines and consensus initially identified, two of them (American College of Rheumatology 2017 and the Brazilian Guidelines 2021) were selected for comparison considering the latter as the most current guides in the LATAM region. Based on this methodology fifty statements were issued. All of them but four (1.20, 1.21, 1.23 and 4.2) attained agreement.

Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicated

Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease

Update on the Treatment of Glucocorticoid-Induced Osteoporosis

A Narrative Review of the Role of Glucocorticoid Receptors in Prostate Cancer: Developments in Last 5 Years

[Glucocorticoid and Bone. The changes of Japanese and foreign guidelines for the management of glucocorticoid-induced osteoporosis]

[Secondary osteoporosis. Guidelines for glucocorticoid-induced osteoporosis]

[Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines]

Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)

Latest on Anabolic Agents for Osteoporosis Treatment

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

Development and Comparison of Treatment Decision Tools for Glucocorticoid-Induced Osteoporosis

Osteoporosis: a discussion on the past 5 years

Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis

Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases

Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

Goal-Directed Osteoporosis Treatment: ASBMR/BHOF Task Force Position Statement 2024

Glucocorticoid-Associated Osteoporosis in Chronic Inflammatory Diseases: Epidemiology, Mechanisms, Diagnosis, and Treatment

Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report